🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

12 results for “efgartigimod” Clear

  1. EFGARTIGIMOD ALFA, JNJ-80202135

    Janssen-Cilag International N.V.

    generalized myasthenia gravis

    phase 3 small molecule active

    1 trial

  2. Efgartigimod PH20 SC

    argenx

    Primary Sjogrens Disease

    phase 3 mab active

    1 trial

  3. Efgartigimod, Placebo for efgartigimod

    argenx

    Thyroid Eye Disease (TED)

    phase 3 small molecule active

    1 trial

  4. Placebo efgartigimod IV concentrate for solution, ARGX-113, Vyvgart 20 mg/mL concentrate for solution for infusion

    argenx

    Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  5. Placebo for efgartigimod, ARGX-113

    argenx

    Chronic Idiopathic thrombocytopenic purpura

    phase 3 small molecule active

    1 trial

  6. Placebo for efgartigimod, ARGX-113, Vyvgart 20 mg/mL concentrate for solution for infusion

    argenx

    Primary Immune thrombocytopenia (ITP)

    phase 3 small molecule active

    1 trial

  7. Vyvgart 1 000 mg solution for injection in pre-filled syringe, Placebo for efgartigimod

    argenx

    Thyroid Eye Disease (TED)

    phase 3 small molecule active

    1 trial

  8. efgartigimod PH20 SC

    argenx

    Bullous Pemphigoid

    phase 3 mab completed

    1 trial

  9. Efgartigimod, ARGX-113

    argenx

    Chronic Inflammatory Demyelinating Polyneuropathy

    phase 2 small molecule active

    1 trial

  10. Placebo PH20 SC – prefilled syringe (placebo to Efgartigimod PH20 SC – prefilled syringe), Efgartigimod

    argenx

    Antibody-Mediated Rejection

    phase 2 small molecule active

    1 trial

  11. A study to assess the effects of efgartigimod on emasiprubart in healthy adult participants

    argenx

    not applicable

    phase 1 other active

    1 trial

  12. Efgartigimod + Telitacicept (1-week interval) group

    The First People's Hospital of Lianyungang

    Myasthenia Gravis

    small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources